Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to -$15.8 million.

  • Cue Biopharma's Net Cash Flow fell 76015.89% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.7 million, marking a year-over-year increase of 696.48%. This contributed to the annual value of -$26.1 million for FY2024, which is 74072.28% down from last year.
  • Latest data reveals that Cue Biopharma reported Net Cash Flow of -$15.8 million as of Q3 2025, which was down 76015.89% from $14.4 million recorded in Q2 2025.
  • Over the past 5 years, Cue Biopharma's Net Cash Flow peaked at $21.9 million during Q4 2022, and registered a low of -$36.4 million during Q3 2022.
  • Its 5-year average for Net Cash Flow is -$3.3 million, with a median of -$3.3 million in 2021.
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 77093.09% in 2022, then plummeted by 76015.89% in 2025.
  • Over the past 5 years, Cue Biopharma's Net Cash Flow (Quarter) stood at -$3.3 million in 2021, then surged by 770.93% to $21.9 million in 2022, then tumbled by 128.22% to -$6.2 million in 2023, then tumbled by 61.29% to -$10.0 million in 2024, then crashed by 58.53% to -$15.8 million in 2025.
  • Its Net Cash Flow stands at -$15.8 million for Q3 2025, versus $14.4 million for Q2 2025 and -$9.3 million for Q1 2025.